Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Detection of Chlamydia (CT) and Gonorrhea (NG)
Clinical Study Protocol for the Illumigene® Chlamydia and Illumigene® Gonorrhea DNA Amplification Assays
Status: Enrolling
Updated:  12/5/2017
Planned Parenthood of the Rocky Mountains
mi
from
Aurora, CO
Detection of Chlamydia (CT) and Gonorrhea (NG)
Clinical Study Protocol for the Illumigene® Chlamydia and Illumigene® Gonorrhea DNA Amplification Assays
Status: Enrolling
Updated: 12/5/2017
Planned Parenthood of the Rocky Mountains
mi
from
Aurora, CO
Click here to add this to my saved trials
Detection of Chlamydia (CT) and Gonorrhea (NG)
Clinical Study Protocol for the Illumigene® Chlamydia and Illumigene® Gonorrhea DNA Amplification Assays
Status: Enrolling
Updated:  12/5/2017
New England Center for Clinical Research
mi
from
Fall River, MA
Detection of Chlamydia (CT) and Gonorrhea (NG)
Clinical Study Protocol for the Illumigene® Chlamydia and Illumigene® Gonorrhea DNA Amplification Assays
Status: Enrolling
Updated: 12/5/2017
New England Center for Clinical Research
mi
from
Fall River, MA
Click here to add this to my saved trials
Detection of Chlamydia (CT) and Gonorrhea (NG)
Clinical Study Protocol for the Illumigene® Chlamydia and Illumigene® Gonorrhea DNA Amplification Assays
Status: Enrolling
Updated:  12/5/2017
Planned Parenthood Southeastern PA
mi
from
Philadelphia, PA
Detection of Chlamydia (CT) and Gonorrhea (NG)
Clinical Study Protocol for the Illumigene® Chlamydia and Illumigene® Gonorrhea DNA Amplification Assays
Status: Enrolling
Updated: 12/5/2017
Planned Parenthood Southeastern PA
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine
Pharmacokinetic Issues in the Use of Moxifloxacin Plus Rifapentine
Status: Enrolling
Updated:  12/5/2017
Johns Hopkins University
mi
from
Baltimore, MD
Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine
Pharmacokinetic Issues in the Use of Moxifloxacin Plus Rifapentine
Status: Enrolling
Updated: 12/5/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
University of California at Davis Health System
mi
from
Sacramento, CA
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
University of California at Davis Health System
mi
from
Sacramento, CA
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
California Pacific Medical Center
mi
from
San Francisco, CA
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
University of California at San Francisco
mi
from
San Francisco, CA
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
Emory Hospital
mi
from
Atlanta, GA
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
Emory Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
University of Chicago, Division of Infectious Diseases
mi
from
Chicago, IL
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
University of Chicago, Division of Infectious Diseases
mi
from
Chicago, IL
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
Indiana BMT
mi
from
Beech Grove, IN
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
Indiana BMT
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
Infectious Disease of Indiana
mi
from
Indianapolis, IN
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
Infectious Disease of Indiana
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
Henry Ford Hospital
mi
from
Detroit, MI
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
Wayne State University School of Medicine
mi
from
Detroit, MI
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
Wayne State University School of Medicine
mi
from
Detroit, MI
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
Upstate Infectious Diseases Association LLP
mi
from
Albany, NY
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
Upstate Infectious Diseases Association LLP
mi
from
Albany, NY
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
Cleveland Clinic
mi
from
Cleveland, OH
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
Regional Infection Diseases Infusion Center Inc.
mi
from
Lima, OH
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
Regional Infection Diseases Infusion Center Inc.
mi
from
Lima, OH
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
Temple University Health Sciences
mi
from
Philadelphia, PA
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
Temple University Health Sciences
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
University of Pittsburgh Medical Center Health System
mi
from
Pittsburgh, PA
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
University of Pittsburgh Medical Center Health System
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
Fred Hutchinson Cancer Research Center, Clinical Research
mi
from
Seattle, WA
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
Fred Hutchinson Cancer Research Center, Clinical Research
mi
from
Seattle, WA
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
Stanford University Hospital
mi
from
Stanford, CA
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
Stanford University Hospital
mi
from
Stanford, CA
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
UMASS Memorial Medical Center
mi
from
Worcester, MA
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
UMASS Memorial Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated:  12/7/2017
Hospital Italiano de Buenos Aires
mi
from
Ciudad Autonoma,
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Status: Enrolling
Updated: 12/7/2017
Hospital Italiano de Buenos Aires
mi
from
Ciudad Autonoma,
Click here to add this to my saved trials
Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests
Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests for the Diagnosis of Pulmonary Tuberculosis in Comparison to Geneexpert MTB/RIF
Status: Enrolling
Updated:  12/8/2017
Johns Hopkins University
mi
from
Baltimore, MD
Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests
Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests for the Diagnosis of Pulmonary Tuberculosis in Comparison to Geneexpert MTB/RIF
Status: Enrolling
Updated: 12/8/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
A Randomized, Multi-Center Trial to Evaluate the Safety & Immunogenicity of Staphylococcus Aureus Toxoids, rAT and rLukS-PV, in Healthy Volunteers
Status: Enrolling
Updated:  12/11/2017
Naval Medical Center - Portsmouth
mi
from
Portsmouth, VA
Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
A Randomized, Multi-Center Trial to Evaluate the Safety & Immunogenicity of Staphylococcus Aureus Toxoids, rAT and rLukS-PV, in Healthy Volunteers
Status: Enrolling
Updated: 12/11/2017
Naval Medical Center - Portsmouth
mi
from
Portsmouth, VA
Click here to add this to my saved trials
Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
A Randomized, Multi-Center Trial to Evaluate the Safety & Immunogenicity of Staphylococcus Aureus Toxoids, rAT and rLukS-PV, in Healthy Volunteers
Status: Enrolling
Updated:  12/11/2017
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
A Randomized, Multi-Center Trial to Evaluate the Safety & Immunogenicity of Staphylococcus Aureus Toxoids, rAT and rLukS-PV, in Healthy Volunteers
Status: Enrolling
Updated: 12/11/2017
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated:  12/12/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated: 12/12/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated:  12/12/2017
University of Colorado
mi
from
Denver, CO
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated: 12/12/2017
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated:  12/12/2017
Henry Ford Hospital
mi
from
Detroit, MI
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated: 12/12/2017
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated:  12/12/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated: 12/12/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated:  12/12/2017
Albert Einstein College of Medicine
mi
from
Bronx, NY
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated: 12/12/2017
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated:  12/12/2017
Carolina Medical Center
mi
from
Charlotte, NC
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated: 12/12/2017
Carolina Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated:  12/12/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated: 12/12/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated:  12/12/2017
The Brody School of Medicine at ECU
mi
from
Greenville, NC
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated: 12/12/2017
The Brody School of Medicine at ECU
mi
from
Greenville, NC
Click here to add this to my saved trials
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated:  12/12/2017
Medical University of South Carolina
mi
from
Charleston, SC
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated: 12/12/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated:  12/12/2017
Greenville Hospital System
mi
from
Greenville, SC
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated: 12/12/2017
Greenville Hospital System
mi
from
Greenville, SC
Click here to add this to my saved trials
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated:  12/12/2017
UT MD Anderson Cancer Center
mi
from
Houston, TX
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated: 12/12/2017
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated:  12/12/2017
University of Mass
mi
from
Worcester, MA
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated: 12/12/2017
University of Mass
mi
from
Worcester, MA
Click here to add this to my saved trials
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated:  12/12/2017
Fundacio Clinic Privada per a la Recera
mi
from
Barcelona,
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated: 12/12/2017
Fundacio Clinic Privada per a la Recera
mi
from
Barcelona,
Click here to add this to my saved trials
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated:  12/12/2017
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated: 12/12/2017
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated:  12/12/2017
William Beaumont Hospital
mi
from
Royal Oak, MI
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Status: Enrolling
Updated: 12/12/2017
William Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/14/2017
GSK Investigational Site
mi
from
Phoenix, AZ
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/14/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/14/2017
GSK Investigational Site
mi
from
Bakersfield, CA
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/14/2017
GSK Investigational Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  12/14/2017
GSK Investigational Site
mi
from
Long Beach, CA
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 12/14/2017
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials